These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 4131046)

  • 21. Adriamycin-induced myocardial lesions. Report of a workshop.
    Am J Surg Pathol; 1977 Mar; 1(1):55-60. PubMed ID: 414633
    [No Abstract]   [Full Text] [Related]  

  • 22. [The heart and drug poisoning, excluding cardiologic treatments].
    Nicolas G; Bouhour JB; Godin JF; Rozo L; Chareyre M
    Arch Mal Coeur Vaiss; 1978 Apr; 71(4):471-6. PubMed ID: 96765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms and selectivity of anthracycline aminoglycosides and other intercalating agents.
    Schwartz HS
    Biomedicine; 1976 Nov; 24(5):317-23. PubMed ID: 187260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.
    Trouet A; Deprez-De Campeneere D
    Cancer Chemother Pharmacol; 1979; 2(1):77-9. PubMed ID: 498424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
    Ferrans VJ
    Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experimental studies on the cytotoxic effects of adriamycin and daunomycin used alone and in combination (author's transl)].
    Cardinali G; Colombi A; Rivelli L; Lai V
    Haematologica; 1978 Apr; 63(2):182-208. PubMed ID: 98401
    [No Abstract]   [Full Text] [Related]  

  • 27. Resuscitation of acute anthracycline-induced cardiogenic shock and refractory hypoxemia with mechanical circulatory supports: Pitfalls and strategies.
    Wu MY; Liu KS; Lin PJ; Haung YK; Tsai FC
    Resuscitation; 2009 Mar; 80(3):385-6. PubMed ID: 19117657
    [No Abstract]   [Full Text] [Related]  

  • 28. [Suppression of DNA synthesis in mice by the anthracycline antibiotics daunorubicin, carminomycin and doxorubicin].
    Reznikova MI; Dudnik IuV
    Antibiot Khimioter; 1988 Apr; 33(4):286-9. PubMed ID: 3389958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Daunomycin-and adriamycin-induced cardiomyopathy--relationship between dosage of drugs and histopathological findings (author's transl)].
    Yamaguchi H; Toyota S; Takahara O; Ichimaru M
    Rinsho Ketsueki; 1978 Aug; 19(8):1041-50. PubMed ID: 713049
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of adriamycin cardiotoxicity by acetyldaunomycin.
    Zbinden G
    Experientia; 1975 Sep; 31(9):1058-60. PubMed ID: 1175747
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of acute granulocytic leukemias.
    Bernard J; Weil M; Jacquillat C
    Annu Rev Med; 1974; 25():39-51. PubMed ID: 4596234
    [No Abstract]   [Full Text] [Related]  

  • 32. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
    Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
    J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimentally developed cellular resistance to daunomycin. Resistance mechanisms, the daunomycin-pump and cross resistance to adriamycin, vincristine and vinblastine.
    Dano K
    Acta Pathol Microbiol Scand Suppl; 1976; (256 Suppl):3-80. PubMed ID: 1068629
    [No Abstract]   [Full Text] [Related]  

  • 34. Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy.
    Dorent R; Pavie A; Nataf P; Tedy G; Vaissier E; Ghoussoub JJ; Bors V; Gandjbakhch I
    Transplant Proc; 1995 Apr; 27(2):1683. PubMed ID: 7725449
    [No Abstract]   [Full Text] [Related]  

  • 35. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
    Schwartz HS
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective inhibition of rat and human cardiac guanylate cyclase by doxorubicin (adriamycin): possible link to anthracycline cardiotoxicity.
    Levey GS; Levey BA; Ruiz E; Lehotay DC
    Trans Assoc Am Physicians; 1979; 92():303-8. PubMed ID: 44927
    [No Abstract]   [Full Text] [Related]  

  • 37. Letter: Contact dermatitis associated with adriamycin (NSC-123127) and daunorubicin (NSC-82151).
    Reich SD; Bachur NR
    Cancer Chemother Rep; 1975; 59(4):677-8. PubMed ID: 1175160
    [No Abstract]   [Full Text] [Related]  

  • 38. Liposomal KS drugs approved.
    GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine.
    Newman RA; Hacker MP; Krakoff IH
    Cancer Res; 1981 Sep; 41(9 Pt 1):3483-8. PubMed ID: 7260911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity.
    Lehotay DC; Levey BA; Rogerson BJ; Levey GS
    Cancer Treat Rep; 1982 Feb; 66(2):311-6. PubMed ID: 6120040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.